Early Treatment with Faricimab Stops Vision Loss in Wet Macular Degeneration

Faricimab is a newer eye medicine that fights wet age‑related macular degeneration, a leading cause of blindness. Researchers in Wales studied people who had never been treated before. They split the patients into two groups: those whose vision was still good (less than 0. 3 logMAR) and those with worse sight (between 0. 6 and 0. 7 logMAR). The early‑treatment group started the drug soon after diagnosis, while the late‑group waited until their vision had already declined.

Results showed that patients who began therapy early kept more of their sight over time, while the late‑group saw less improvement. This suggests that waiting for vision to drop before treating can let damage become harder to reverse. The study uses real‑world data, meaning the results come from everyday clinical practice rather than a controlled trial. Clinicians can use these findings to explain the importance of prompt treatment to patients and families.

Actions